OpenAI-Novo Nordisk Partnership Targets AI Drug Discovery

The partnership has aimed to speed up drug discovery, with a particular focus on obesity and diabetes. Pilot programs have begun in Novo Nordisk’s R&D, commercial, and manufacturing teams, supporting broader use of AI across the company.

OpenAI has formed a strategic partnership with pharmaceutical company Novo Nordisk to apply advanced AI in drug discovery, such as processing complex datasets, pinpointing potential drug candidates, and reducing the timeline from research to patient treatment.

Under this collaboration, OpenAI has assisted in enhancing the AI skills of Novo Nordisk’s global employees.

Novo Nordisk has deployed OpenAI’s technology to optimize manufacturing processes, corporate functions, and supply chain and distribution activities.

The partnership has incorporated data protection measures, human supervision, and governance protocols to promote ethical AI application and regulatory compliance.

"This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives," Mike Doustdar, president and CEO of Novo Nordisk, said in a statement.

"Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before."

The companies said pilot programs would launch in Novo Nordisk’s R&D, commercial, and manufacturing operations, with complete integration of OpenAI’s technology expected by year-end.

"AI is reshaping industries, and in life sciences, it can help people live better, longer lives," Sam Altman, CEO of OpenAI, said in a statement. "This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care."

In a related recent development, the Gates Foundation and OpenAI have launched the $50 million Horizon1000 initiative in January 2026 to scale AI across 1,000 African primary health clinics, starting in Rwanda, by providing tools for triage, referrals, and efficiency to address workforce shortages and improve care access.

Stay tuned for more such updates on Digital Health News